Details der Publikation - Pharmacotherapeutic management of pediatric lymphoma

Pharmacotherapeutic management of pediatric lymphoma / Christine Mauz-Körholz, Natascha Ströter, Julia Baumann, Ante Botzen, Katharina Körholz, Dieter Körholz

Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL) comprise approximately 15% of all childhood malignancies. Cure rates for both lymphoma entities have evolved tremendously during the last couple of decades, raising the 5-year survival rates to almost 100% for HL and to 85% for NHL. The mainstay therapy for both malignancies is still chemotherapy-with different regimens recommended for different types of disease. In HL, combined modality treatment, i.e., chemotherapy followed by radiotherapy, has long been the standard regimen. In order to reduce long-term side effects, such as second malignancies, most major pediatric HL consortia have studied response-based radiotherapy reduction strategies over the last 3 decades. For recurrent disease, high-dose chemotherapy followed by an autologous or an allogeneic hematopoietic stem-cell transplant is an option. No targeted agents have yet gained regulatory approval for use in pediatric patients with lymphoma. For adult lymphoma patients, the CD20 antibody rituximab and the CD30 antibody-drug conjugate brentuximab vedotin are targeted agents used regularly in first- and second-line treatment regimens. More recently, immune checkpoint inhibitors, phosphatidyl-inositol-3-kinase inhibitors, and Bruton's tyrosine kinase inhibitors appear to be very promising new treatment options in adult lymphoma. Here, we discuss the current experience with these types of agents in pediatric lymphoma patients..

Medienart:	E-Artikel

Erscheinungsjahr:	2018
Erschienen:	2018

Enthalten in:	Zur Gesamtaufnahme - volume:20
Enthalten in:	Pediatric drugs - 20(2018), 1, Seite 43-57

Sprache:	Englisch

Beteiligte Personen:	Mauz-Körholz, Christine, 1963- [VerfasserIn] Ströter, Natascha [VerfasserIn] Baumann, Julia [VerfasserIn] Botzen, Ante [VerfasserIn] Körholz, Katharina, 1993- [VerfasserIn] Körholz, Dieter [VerfasserIn]

Links:	Volltext [lizenzpflichtig]

Themen:	Adolescent Antineoplastic Agents Child Child, Preschool Humans Lymphoma Lymphoma, Non-Hodgkin

Anmerkungen:	First published: 10 November 2017 Gesehen am 23.03.2020

Umfang:	15

doi:	10.1007/s40272-017-0265-x

funding:
Förderinstitution / Projekttitel:

PPN (Katalog-ID):	1693129779

Internformat


LEADER	01000caa a2200265 4500
001	1693129779
003	DE-627
005	20230428194302.0
007	cr uuu---uuuuu
008	200323r20182017xx \|\|\|\|\|o 00\| \|\|eng c
024	7		\|a 10.1007/s40272-017-0265-x \|2 doi
035			\|a (DE-627)1693129779
035			\|a (DE-599)KXP1693129779
035			\|a (OCoLC)1341310602
040			\|a DE-627 \|b ger \|c DE-627 \|e rda
041			\|a eng
100	1		\|a Mauz-Körholz, Christine \|d 1963- \|e verfasserin \|0 (DE-588)128485213 \|0 (DE-627)373394497 \|0 (DE-576)170657566 \|4 aut
245	1	0	\|a Pharmacotherapeutic management of pediatric lymphoma \|c Christine Mauz-Körholz, Natascha Ströter, Julia Baumann, Ante Botzen, Katharina Körholz, Dieter Körholz
264		1	\|c 2018
300			\|a 15
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
500			\|a First published: 10 November 2017
500			\|a Gesehen am 23.03.2020
520			\|a Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL) comprise approximately 15% of all childhood malignancies. Cure rates for both lymphoma entities have evolved tremendously during the last couple of decades, raising the 5-year survival rates to almost 100% for HL and to 85% for NHL. The mainstay therapy for both malignancies is still chemotherapy-with different regimens recommended for different types of disease. In HL, combined modality treatment, i.e., chemotherapy followed by radiotherapy, has long been the standard regimen. In order to reduce long-term side effects, such as second malignancies, most major pediatric HL consortia have studied response-based radiotherapy reduction strategies over the last 3 decades. For recurrent disease, high-dose chemotherapy followed by an autologous or an allogeneic hematopoietic stem-cell transplant is an option. No targeted agents have yet gained regulatory approval for use in pediatric patients with lymphoma. For adult lymphoma patients, the CD20 antibody rituximab and the CD30 antibody-drug conjugate brentuximab vedotin are targeted agents used regularly in first- and second-line treatment regimens. More recently, immune checkpoint inhibitors, phosphatidyl-inositol-3-kinase inhibitors, and Bruton's tyrosine kinase inhibitors appear to be very promising new treatment options in adult lymphoma. Here, we discuss the current experience with these types of agents in pediatric lymphoma patients.
534			\|c 2017
650		4	\|a Adolescent
650		4	\|a Antineoplastic Agents
650		4	\|a Child
650		4	\|a Child, Preschool
650		4	\|a Humans
650		4	\|a Lymphoma
650		4	\|a Lymphoma, Non-Hodgkin
700	1		\|a Ströter, Natascha \|e verfasserin \|4 aut
700	1		\|a Baumann, Julia \|e verfasserin \|4 aut
700	1		\|a Botzen, Ante \|e verfasserin \|4 aut
700	1		\|a Körholz, Katharina \|d 1993- \|e verfasserin \|0 (DE-588)1206894180 \|0 (DE-627)1693130580 \|4 aut
700	1		\|a Körholz, Dieter \|e verfasserin \|4 aut
773	0	8	\|i Enthalten in \|t Pediatric drugs \|d Berlin [u.a.] : Springer, 1999 \|g 20(2018), 1, Seite 43-57 \|h Online-Ressource \|w (DE-627)327644214 \|w (DE-600)2043681-6 \|w (DE-576)273880802 \|x 1179-2019 \|7 nnns
773	1	8	\|g volume:20 \|g year:2018 \|g number:1 \|g pages:43-57 \|g extent:15
856	4	0	\|u https://doi.org/10.1007/s40272-017-0265-x \|x Verlag \|x Resolving-System \|z lizenzpflichtig \|3 Volltext
912			\|a GBV_USEFLAG_U
912			\|a GBV_ILN_2013
912			\|a ISIL_DE-16-250
912			\|a SYSFLAG_1
912			\|a GBV_KXP
912			\|a SSG-OLC-PHA
912			\|a GBV_ILN_11
912			\|a GBV_ILN_20
912			\|a GBV_ILN_22
912			\|a GBV_ILN_23
912			\|a GBV_ILN_24
912			\|a GBV_ILN_31
912			\|a GBV_ILN_32
912			\|a GBV_ILN_39
912			\|a GBV_ILN_40
912			\|a GBV_ILN_60
912			\|a GBV_ILN_62
912			\|a GBV_ILN_63
912			\|a GBV_ILN_65
912			\|a GBV_ILN_69
912			\|a GBV_ILN_70
912			\|a GBV_ILN_73
912			\|a GBV_ILN_74
912			\|a GBV_ILN_90
912			\|a GBV_ILN_95
912			\|a GBV_ILN_100
912			\|a GBV_ILN_101
912			\|a GBV_ILN_105
912			\|a GBV_ILN_110
912			\|a GBV_ILN_120
912			\|a GBV_ILN_138
912			\|a GBV_ILN_150
912			\|a GBV_ILN_151
912			\|a GBV_ILN_161
912			\|a GBV_ILN_170
912			\|a GBV_ILN_171
912			\|a GBV_ILN_187
912			\|a GBV_ILN_213
912			\|a GBV_ILN_230
912			\|a GBV_ILN_250
912			\|a GBV_ILN_266
912			\|a GBV_ILN_281
912			\|a GBV_ILN_285
912			\|a GBV_ILN_293
912			\|a GBV_ILN_370
912			\|a GBV_ILN_602
912			\|a GBV_ILN_636
912			\|a GBV_ILN_702
912			\|a GBV_ILN_2001
912			\|a GBV_ILN_2003
912			\|a GBV_ILN_2004
912			\|a GBV_ILN_2005
912			\|a GBV_ILN_2006
912			\|a GBV_ILN_2007
912			\|a GBV_ILN_2008
912			\|a GBV_ILN_2009
912			\|a GBV_ILN_2010
912			\|a GBV_ILN_2011
912			\|a GBV_ILN_2014
912			\|a GBV_ILN_2015
912			\|a GBV_ILN_2020
912			\|a GBV_ILN_2021
912			\|a GBV_ILN_2025
912			\|a GBV_ILN_2026
912			\|a GBV_ILN_2027
912			\|a GBV_ILN_2031
912			\|a GBV_ILN_2034
912			\|a GBV_ILN_2037
912			\|a GBV_ILN_2038
912			\|a GBV_ILN_2039
912			\|a GBV_ILN_2044
912			\|a GBV_ILN_2048
912			\|a GBV_ILN_2049
912			\|a GBV_ILN_2050
912			\|a GBV_ILN_2055
912			\|a GBV_ILN_2057
912			\|a GBV_ILN_2059
912			\|a GBV_ILN_2061
912			\|a GBV_ILN_2064
912			\|a GBV_ILN_2065
912			\|a GBV_ILN_2068
912			\|a GBV_ILN_2088
912			\|a GBV_ILN_2093
912			\|a GBV_ILN_2106
912			\|a GBV_ILN_2107
912			\|a GBV_ILN_2108
912			\|a GBV_ILN_2110
912			\|a GBV_ILN_2111
912			\|a GBV_ILN_2112
912			\|a GBV_ILN_2113
912			\|a GBV_ILN_2118
912			\|a GBV_ILN_2129
912			\|a GBV_ILN_2143
912			\|a GBV_ILN_2144
912			\|a GBV_ILN_2147
912			\|a GBV_ILN_2148
912			\|a GBV_ILN_2152
912			\|a GBV_ILN_2153
912			\|a GBV_ILN_2188
912			\|a GBV_ILN_2190
912			\|a GBV_ILN_2232
912			\|a GBV_ILN_2336
912			\|a GBV_ILN_2446
912			\|a GBV_ILN_2470
912			\|a GBV_ILN_2472
912			\|a GBV_ILN_2507
912			\|a GBV_ILN_2522
912			\|a GBV_ILN_2548
912			\|a GBV_ILN_4012
912			\|a GBV_ILN_4035
912			\|a GBV_ILN_4037
912			\|a GBV_ILN_4046
912			\|a GBV_ILN_4112
912			\|a GBV_ILN_4125
912			\|a GBV_ILN_4242
912			\|a GBV_ILN_4246
912			\|a GBV_ILN_4249
912			\|a GBV_ILN_4251
912			\|a GBV_ILN_4305
912			\|a GBV_ILN_4306
912			\|a GBV_ILN_4307
912			\|a GBV_ILN_4313
912			\|a GBV_ILN_4322
912			\|a GBV_ILN_4323
912			\|a GBV_ILN_4324
912			\|a GBV_ILN_4325
912			\|a GBV_ILN_4326
912			\|a GBV_ILN_4333
912			\|a GBV_ILN_4334
912			\|a GBV_ILN_4335
912			\|a GBV_ILN_4336
912			\|a GBV_ILN_4338
912			\|a GBV_ILN_4393
912			\|a GBV_ILN_4700
936	u	w	\|d 20 \|j 2018 \|e 1 \|h 43-57 \|g 15
951			\|a AR
952			\|d 20 \|j 2018 \|e 1 \|h 43-57 \|g 15
980			\|2 2013 \|1 01 \|x DE-16-250 \|b 3611954446 \|c 00 \|f --%%-- \|d --%%-- \|e --%%-- \|j --%%-- \|y l01 \|z 23-03-20
982			\|2 2013 \|1 01 \|x DE-16-250 \|8 00 \|s s \|a hd2018
982			\|2 2013 \|1 01 \|x DE-16-250 \|8 01 \|s s \|0 (DE-627)1410508463 \|a wissenschaftlicher Artikel (Zeitschrift)
982			\|2 2013 \|1 01 \|x DE-16-250 \|8 02 \|s s \|a per_6
982			\|2 2013 \|1 01 \|x DE-16-250 \|8 03 \|s s \|a s_15
982			\|2 2013 \|1 01 \|x DE-16-250 \|8 04 \|s p \|0 (DE-627)1693131005 \|a Körholz, Katharina
982			\|2 2013 \|1 01 \|x DE-16-250 \|8 04 \|s k \|0 (DE-627)1416466967 \|a Medizinische Fakultät Heidelberg
982			\|2 2013 \|1 01 \|x DE-16-250 \|8 04 \|s s \|0 (DE-627)1410501914 \|a Verfasser
982			\|2 2013 \|1 01 \|x DE-16-250 \|8 04 \|s s \|a pos_5

Pharmacotherapeutic management of pediatric lymphoma / Christine Mauz-Körholz, Natascha Ströter, Julia Baumann, Ante Botzen, Katharina Körholz, Dieter Körholz

Zugang & Verfügbarkeit

Zugehörige Publikationen/Bände